As published in their initiating research note from Piper Sandler on May 31, 2024, Elevation Oncology Inc [ELEV] has been an Overweight and the price target has been revised to $10. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid May. As of March 01, 2024, JMP Securities has initiated its “Mkt outperform” rating for ELEV. Earlier on May 30, 2023, SVB Securities upgraded its rating. Their new recommendation was “an Outperform” for ELEV stock which previously was a “a Market perform”.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Analyzing ELEV Stock Performance
During the last five days, there has been a surge of approximately 13.24%. Over the course of the year, Elevation Oncology Inc shares have jumped approximately 24.69%. Shares of the company reached a 52-week high of $5.8299 on 04/03/24 and a 52-week low of $0.5000 on 10/10/24. A 50-day SMA is recorded $0.5883, while a 200-day SMA reached $2.2905. Nevertheless, trading volume fell to 1.21 million shares from 1.11 million shares the previous day.
Support And Resistance Levels for Elevation Oncology Inc (ELEV)
According to the 24-hour chart, there is a support level at 0.6186, which, if violated, would cause prices to drop to 0.5675. In the upper region, resistance lies at 0.7653. The next price resistance is at 0.8609. RSI (Relative Strength Index) is 55.97 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0802, which suggests the price will decrease in the coming days. Percent R is at 56.92%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Elevation Oncology Inc (ELEV)?
On December 23, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and initiated coverage with a $12.
